

MAILED TO: DR. DOROTHY DOBBS
1600 S. Eads St., Apt. 432N
Arlington, Virginia 22202

July 23, 1970

Dr. Dorothy Dobbs
Section of Neuropharmacology
Food and Drug Administration
Washington, D.C.

Dear Dorothy,

It was a pleasure talking with you today, and finding that our views on the proposed guidelines for drug evaluations were essentially in agreement, reassured me. Thanks.

Enclosed is a copy of the summary of the June 4 meeting on *Narcotic Antagonists in Opiate Dependence*. It will be published in *Science*. The participants included clinicians, pharmacologists and chemists with experience in the antagonists. We concluded that: (1) The antagonist model was both clinically useful and theoretically interesting; (2) Available antagonists, cyclazocine and naloxone, were safe and further studies should continue; (3) A long-acting antagonist was the ideal immunizing agent and every effort should be made to enhance such a development.

We are continuing our clinical studies of cyclazocine; have been reassured (after much difficulty [see *New York Times*, August 14]) of our supplies of naloxone for one year; and have contract support from the New York State Narcotic Addiction Control Commission to develop a long acting antagonist. (We also are continuing a methadone maintenance program and are studying the duration of *l*-alpha-acetylmethadol, using heroin challenges as our index of duration of cross-tolerance.)

It would be an honor, and interesting, to participate in the FDA committee program. There is surely need for continuing evaluations of the methadone and other opiate treatment programs. My curriculum vitae is enclosed; and I have been cleared for U. S. governmental activity.

My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kt

enc.